Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

Two teams of scientists have recently come up with potential breakthroughs with preventing a serious side effect of Parkinson ...

Philip Stevens, a 66-year-old from Hampshire, has received £70,000 from his GP following a lawsuit after he was given the ...

The new Ochsner site will contribute to uncovering additional genes as well as examine health disparities and care access for ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Commonly prescribed drugs could increase risk of dementia, scientists have warned. Research conducted by the University of ...

Dr James Pickett, Head of Research at Alzheimer’s Society, warned commonly-prescribed drugs that treat conditions including ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

Taking certain types of drugs could increase the risk of developing dementia later in life, a study has found. Regular use of ...

(Reuters) -AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study.

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.